Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue

Stock Track

06/30

Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.

The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.

Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1130284797"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130284797\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130284797?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130284797","market":"nz","top_or_hot":-1,"title":"Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue","media":"Stock Track","content":"<p>Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.</p><p>The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neuren Pharmaceuticals Soars 5.30% Intraday on Positive European Regulatory News for Daybue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-30 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.</p><p>The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1130284797","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130284797","pubTimestamp":1782777748,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Neuren Pharmaceuticals盘中大涨5.30%欧洲监管利好Daybue","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals Ltd (NEU.AU) experienced a significant price surge of 5.30% during intraday trading on Tuesday, reflecting strong investor optimism following positive regulatory developments.The stock movement appears to be driven by news that Neuren is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027. This follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients.Final approval now depends on the European Commission's decision, which is expected in the coming months. Analyst firm Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals, reinforcing positive sentiment around the company's prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}